Novel antifungal activity of purpurin against Candida species in vitro

Medical Mycology

Volumn 48, Issue 7, 2010, Pages 904-911

  Kang, Kai ^a   Fong, Wing Ping ^a   Tsang, Paul Wai Kei ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Candida; Efflux pumps; In vitro susceptibility; Mitochondrial membrane potential; Purpurin

Indexed keywords

ANTIFUNGAL AGENT; PURPURIN; RHODAMINE 6G;

ANTIFUNGAL ACTIVITY; APOPTOSIS; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; EUKARYOTIC CELL; KLUYVEROMYCES MARXIANUS; MEMBRANE CHANNEL; MEMBRANE DEPOLARIZATION; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; RUBIA;

ANTHRAQUINONES; ANTIFUNGAL AGENTS; CANDIDA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE POTENTIALS; MICROBIAL SENSITIVITY TESTS; MITOCHONDRIA;

CANDIDA; EUKARYOTA; RUBIA TINCTORUM;

EID: 77957740642     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693781003739351     Document Type: Article

References (41)

1. Corner BE, Magee PT. Candida pathogenicity: unraveling the threads of infection. Curr Biol 1997; 7: R691-R694.
2. Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol 2007; 45: 569-587.
3. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mecha-nisms of resistance, and correlation of these mechanisms with bacte-rial resistance. Clin Microbiol Rev 1999; 12: 501-507.
4. Tournu H, Serneels J, van Dijck P. Fungal pathogens research: novel and improved molecular approaches for the discovery of antifungal drug targets. CurrDrug Targets 2005; 6: 909-922.
5. Del Sorbo G, Schoonbeek H, De Waard MA. Fungal transporters involved in eff ux of natural toxic compounds and fungicides. Fungal Genet Biol 2000; 30: 1-15.
6. Carrillo-Muñoz AJ, Giusiano G, Ezkurra PA, Quindós G. Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 2006; 19: 130-139.
7. Samaranayake LP. Candida krusei infections and f uconazole therapy. Hong Kong Med J 1997; 3: 312-314.
8. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungae-mia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-260.
9. Morschh ä user J. Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 2010; 47: 94-106.
10. Muñoz P, Sánchez-Somolinos M, Alcalá L, et al. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Anti-microb Chemother 2005; 55: 188-193.
11. Ríos JL, Recio MC. Medicinal plants and antimicrobial activity. J Ethnopharmacol 2005; 100: 80-84.
12. Agarwal SK, Singh S, Verma S, Kumar S. Antifungal activity of anthraquinone derivatives from Rheum emodi. J Ethnopharmacol 2000; 72:43-46.
13. Kong WJ, Wang JB, Jin C, et al. Effect of emodin on Candida albicans growth investigated by microcalorimetry combined with chemometric analysis. Appl Microbiol Biotechnol 2009; 83: 1183-1190.
14. Xiang W, Song QS, Zhang HJ, Guo SP. Antimicrobial anthraquinones from Morinda angustifolia. Fitoterapia 2008; 79: 501-504.
15. Samaranayake LP, MacFarlane TW, Lamey PJ, Ferguson MM. A comparison of oral rinse and imprint sampling techniques for the detection of yeast, coliform and Staphylococcus aureus carriage in the oral cavity. J Oral Pathol 1986; 15: 386-388.
16. National Committee for Clinical laboratory Standards. 2002. Refer-ence method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd edn. Wayne, PA: National Committee for Clinical Laboratory Standards.
17. Cuenca-Estrella M, Díaz-Guerra TM, Mellado E, Rodríguez- Tudela JL. Inf uence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol 2001; 39: 525-532.
18. Kustimur S, Kalkanci A, Mansuroglu H, Senel K. Evaluation of the disc diffusion method with a comparison study for f uconazole sus-ceptibility of Candida strains. Chin Med J 2003; 116: 633-636.
19. Oliveira ER, Fothergill AW, Kirkpatrick WR, etal. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata Antimicrob Agents Chemother 2005; 49: 3544-3545.
20. Kang K, Wong KS, Seneviratne CJ, et al. In vitro synergistic effects of metergoline and antifungal agents against Candida krusei. Mycoses 2009 June. Available from: http://www3. interscience. wiley. com/cgi-bin/fulltext/ 122457701/PDFSTART.
21. Holmes AR, Lin YH, Niimi K, et al. ABC transporter Cdr1p con-tributes more than Cdr2p does to f uconazole eff ux in f uconazole-resistant Candida albicans clinical isolates. Antimicrob Agents Chemother 2008; 52: 3851-3862.
22. Pina-Vaz C, Sansonetty F, Rodrigues AG, et al. Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifun-gals. Clin Microbiol Infect 2001; 7: 609-618.
23. Pfaller MA, Diekema DJ, Gibbs DL, et al. Candida krusei, a multi-drug-resistant opportunistic fungal pathogen: geographic and tempo-ral trends from the ARTEMIS DISK antifungal surveillance program, 2001 to 2005. J Clin Microbiol 2008; 46: 515-521.
24. Lamping E, Ranchod A, Nakamura K, et al. Abc1p is a multidrug eff ux transporter that tips the balance in favour of innate azole resistance in Candida krusei. Antimicrob Agents Chemother 2009; 53: 354-369.
25. Marczylo TH, Hayatsu T, Arimoto-Kobayashi S, et al. Protection against the bacterial mutagenicity of heterocyclic amines by purpurin, a natural anthraquinone pigment. MutatRes 1999; 444: 451-461.
26. Takahashi E, Fujita KI, Kamataki T, et al. Inhibition of human cyto-chrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpu-rin and alizarin. Mutat Res 2002; 508: 147-156.
27. Piddock LJ. Clinically relevant chromosomally encoded multidrug resis-tance eff ux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
28. Gatti L, Beretta GL, Cossa G, Zunino F, Perego P. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem 2009; 9: 1102-1112.
29. Prasad R, Kapoor K. Multidrug resistance in yeast Candida. Int Rev-Cytol 2005; 242: 215-248.
30. Olver WJ, Scott F, Shankland GS. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin. Med Mycol 2006; 44:655-657.
31. Guo Q, Sun S, Yu J, Li Y, Cao L. Synergistic activity of azoles with ami-odanrone against clinically resistant Candida albicans tested by che-querboard and time-kill methods. JMed Microbiol 2008; 57: 457-462.
32. Huang S, Cao YY, Dai BD et al. In vitro synergism of f uconazole and baicalein against clinical isolates of Candida albicans resistant to f uconazole. Biol Pharm Bull 2008; 31: 2234-2236.
33. Wang C, Youle RJ. The role of mitochondria in apoptosis. Annu Rev-Genet 2009; 43:95-118.
34. Madeo F, Forhlich E, Forhlich KU. A yeast mutant showing diagnostic markers of early and late apoptosis. J Cell Biol 1997; 139: 729-734.
35. Madeo F, Herker E, Wissing S et al. Apoptosis in yeast. Curr Opin Microbiol 2004; 7: 655-660.
36. Ramsdale M. Programmed cell death in pathogenic fungi. Biochim Biophys Acta 2008; 1783: 1369-1380.
37. Wissing S, Ludovico P, Herker E, et al. An AIF orthologues regulates apoptosis in yeast. J Cell Biol 2004; 166: 969-974.
38. Madeo F, Herker E, Maldener C, et al. A caspase-related protease regulates apoptosis in yeast. Mol Cell 2002; 9: 911-917.
39. Phillips AJ, Sudbery I, Ramsdale M. Apoptosis induced by environ-mental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci USA 2003; 100: 14327-14332.
40. Phillips AJ, Crowe JD, Ramsdale M. Ras pathway signaling ac-celerates programmed cell death in the pathogenic fungus Candida albicans. Proc Natl Acad Sci USA 2006; 103: 726-731.
41. Cao YY, Huang S, Dai BD, et al. Candida albicans cells lacking CaMCA1-encoded metacaspase show resistance to oxidative stress-induced death and change in energy metabolism. Fungal Genet Biol 2009; 46: 183-189.